Skip to search formSkip to main contentSkip to account menu

GI 147211

Known as: GI-147211, GI147211 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2005
Review
2005
PURPOSE Liposomal lurtotecan (OSI-211) is a liposomal formulation of the water-soluble topoisomerase I inhibitor lurtotecan… 
2000
2000
BACKGROUND GI147211 is a water-soluble synthetic analogue of camptothecin showing promising in vivo and in vitro antitumor… 
2000
2000
BACKGROUND GI147211, a 10,11-ethylenedioxy substituted analogue of camptothecin (CPT), was brought into clinical development… 
Highly Cited
1998
Highly Cited
1998
Purpose: We have previously reported that DX-8951f, a water-soluble and nonprodrug camptothecin (CPT) derivative, exhibits both… 
1998
1998
GI1147211 is a 7-substituted 10,11-ethylenedioxy-20(S)-camptothecin analogue that inhibits the nuclear enzyme topoisomerase I. In… 
1998
1998
GI147211 is a novel, totally synthetic camptothecin with promising preclinical and early clinical activity. This study was… 
Review
1997
Review
1997
Topoisomerase I inhibitors constitute a new class of anti-cancer agents. Recently, topotecan and irinotecan were registered for… 
1997
1997
Topoisomerase I inhibitors are new compounds of interest for cancer chemotherapy. We performed a study with GI147211, a new… 
1996
1996
Topoisomerase I inhibitors are interesting anti-cancer agents with a novel mechanism of action. We performed a phase I study with…